CoChat

Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?

Open access

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

Tolvaptan is a vasopressin V(2)-receptor antagonist that has shown promise in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). Tolvaptan was, however, associated with liver injury in some ADPKD patients. Inhibition of bile acid transporters may be contributing factors to drug-induced liver injury. In this study, the ability of tolvaptan and two metabolites, DM-4103 and DM-4107, to inhibit human hepatic transporters (NTCP, BSEP, MRP2, MRP3, and MRP4) and bile acid transport in sandwich-cultured human hepatocytes (SCHH) was explored. IC(50) values were determined for tolvaptan, DM-4103 and DM-4107 inhibition of NTCP (∼41.5, 16.3, and 95.6 μM, respectively), BSEP (31.6, 4.15, and 119 μM, respectively), MRP2 (>50, ∼51.0, and >200 μM, respectively), MRP3 (>50, ∼44.6, and 61.2 μM, respectively), and MRP4 (>50, 4.26, and 37.9 μM, respectively). At the therapeutic dose of tolvaptan (90 mg), DM-4103 exhibited a C(max)/IC(50) value >0.1 for NTCP, BSEP, MRP2, MRP3, and MRP4. Tolvaptan accumulation in SCHH was extensive and not sodium-dependent; intracellular concentrations were ∼500 μM after a 10-min incubation duration with tolvaptan (15 μM). The biliary clearance of taurocholic acid (TCA) decreased by 43% when SCHH were co-incubated with tolvaptan (15 μM) and TCA (2.5 μM). When tolvaptan (15 μM) was co-incubated with 2.5 μM of chenodeoxycholic acid, taurochenodeoxycholic acid, or glycochenodeoxycholic acid in separate studies, the cellular accumulation of these bile acids increased by 1.30-, 1.68-, and 2.16-fold, respectively. Based on these data, inhibition of hepatic bile acid transport may be one of the biological mechanisms underlying tolvaptan-associated liver injury in patients with ADPKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/toxsci/kfv231

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Research works printed but not linked: 2

  1. Phillips M. J. Poucell S. Patterson J. Valencia P. (1987). Cholestasis. In The Liver: An Atlas and Text of Ultrastructural Pathology ( Phillips M. J. Poucell S. Patterson J. Valencia P. , Eds.), pp. 101–158. Raven Press, New York.
  2. Qualyst Transporter Solutions Technical Application Bulletin TAB Biol 005. (2011). TAB Biol 005v2.

Cited by

See all 53

Metadata

Authors
Slizgi, J. R., Lu, Y., Brouwer, K. R., St. Claire, R. L., Freeman, K. M., Pan, M., Brock, W. J., & Brouwer, K. L. R.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Otsuka Pharmaceutical Development & Commercialization, Inc. (United States) (US)
Corresponding author
Brouwer, Kim L. R.
Venue
Toxicological Sciences
Published
2015-10-26
Volume
149
Issue
1
Pages
237-250
ISSN
  • 1096-0929 (ISSN-L)
  • 1096-6080
OpenAlex
W2273286870
Cited by
53
References
78
Citations by year
2026: 3 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 5
FWCI
2.62
Type
journal article
Language
en
Open access
Locations
  • Toxicological Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • American Association of Pharmaceutical Scientists
  • Otsuka Pharmaceutical
  • Otsuka Pharmaceutical Development and Commercialization
  • National Institute of General Medical Sciences (R01GM041935)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
tolvaptan, drug-induced liver injury, bile acid transporters, normal tissue complication probability, bile salt export pump, MRP2, MRP3, MRP4, autosomal dominant polycystic kidney disease, hepatotoxicity, taurocholate, chenodeoxycholic acid, biliary excretion
MeSH terms
Tolvaptan, Multidrug Resistance-Associated Protein 2, Animals, Benzazepines, Carrier Proteins, Cricetulus, Humans, Membrane Glycoproteins, Taurocholic Acid, CHO Cells, Polycystic Kidney, Autosomal Dominant, Hepatocytes, ATP-Binding Cassette, Sub-Family C Proteins, Chemical and Drug Induced Liver Injury, Antidiuretic Hormone Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.